Back to Search
Start Over
Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study.
- Source :
- Molecular Imaging & Biology; Jun2021, Vol. 23 Issue 3, p456-466, 11p
- Publication Year :
- 2021
-
Abstract
- Purpose: Imaging is central to the diagnosis and management of Pancreatic Ductal Adenocarcinoma (PDAC). This study evaluated if positron emission tomography (PET)/magnetic resonance imaging (MRI) elicited treatment modifications in PDAC when compared to standard of care imaging (SCI). Procedures: This retrospective study included consecutive patients with PDAC who underwent 2-deoxy-2-[<superscript>18</superscript>F]fluoro-d-glucose ([<superscript>18</superscript>F]F-FDG) PET/MRI and SCI from May 2017 to January 2019. SCI included abdominal computed tomography (CT), MRI, and/or PET/CT. For patients who had more than one pair of PET/MRI and SCI, each management decision was independently evaluated. Treatment strategies based on each modality were extracted from electronic medical records. Follow-up was evaluated until January 2020. Results: Twenty-five patients underwent 37 PET/MRI's, mean age was 65 ± 9 years and 13 (13/25, 52 %) were men. 49 % (18/37, 95 % CI 33–64 %) of the PET/MRI scans changed clinical management. Whether the SCI included a PET/CT or not did not significantly modify the probability of management change (OR = 0.9, 95 % CI 0.2–4, p = 1). One hundred percent (33/33) of the available follow-up data confirmed PET/MRI findings. Conclusions: PET/MRI significantly changed PDAC management, consistently across the different SCI modalities it was compared to. These findings suggest a role for PET/MRI in the management of PDAC. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15361632
- Volume :
- 23
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Molecular Imaging & Biology
- Publication Type :
- Academic Journal
- Accession number :
- 150151455
- Full Text :
- https://doi.org/10.1007/s11307-020-01569-7